Quinazoline-based multi-tyrosine kinase inhibitors: Synthesis, modeling, antitumor and antiangiogenic properties

European Journal of Medicinal Chemistry

Volumn 67, Issue , 2013, Pages 373-383

  Conconi, Maria Teresa ^a   Marzaro, Giovanni ^a   Urbani, Luca ^a   Zanusso, Ilenia ^a   Di Liddo, Rosa ^a   Castagliuolo, Ignazio ^a   Brun, Paola ^a   Tonus, Francesca ^a   Ferrarese, Alessandro ^a   Guiotto, Adriano ^a   Chilin, Adriana ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Angiogenesis; Anilinoquinazoline; Cancer therapy; Multi kinase inhibitors

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANGIOGENESIS INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; IC 50; MOLECULAR MODEL;

3-(4,5-DIMETHYLTHIAZOL-2-YL)-2,5-DIMETHYLTETRAZOLIUM BROMIDE; 3-(N-MORPHOLINO)PROPANESULFONIC ACID; 4′,6-DIAMIDINO-2-PHENYLINDOLE; ADT; ANGIOGENESIS; ANILINOQUINAZOLINE; AUTODOCK TOOLS; BOVINE SERUM ALBUMIN; BSA; CAN; CANCER THERAPY; CERIUM AMMONIUM NITRATE; DAPI; DIMETHYLFORMAMIDE; DITHIOTHREITOL; DMEM; DMF; DTT; DULBECCO'S MODIFIED EAGLE MEDIUM; EC; EDTA; EGF; EGFR; EGTA; ELISA; ENDOTHELIAL CELL; ENZYME-LINKED IMMUNOASSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYLENE GLYCOL TETRAACETIC ACID; ETHYLENEDIAMINETETRAACETIC ACID; FBS; FCS; FETAL BOVINE SERUM; FETAL CALF SERUM; FGF; FGFR-1; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GFR; GROWTH FACTOR REDUCED; HEXAMETHYLENETETRAMINE; HMTA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; HUVEC; IGF; INSULIN-LIKE GROWTH FACTOR; MOPS; MTT; MULTI-KINASE INHIBITORS; PDB; PDGF; PDGFRΒ; PLATELET-DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR RECEPTOR Β; PROTEIN DATA BANK; RECEPTOR TYROSINE KINASE; RTK; SDS-PAGE; SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL ELECTROPHORESIS; TEA; TETRAHYDROFURAN; TFA; THF; TK; TKI; TRIETHYLAMINE; TRIFLUOROACETIC ACID; TYROSINE KINASE; TYROSINE KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1 AND 2; VEGF; VEGFR-1 AND 2;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HT29 CELLS; HUMANS; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84882464940     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.06.057     Document Type: Article

References (43)

1. K. Collins, T. Jacks, N.P. Pavletich, The cell cycle and cancer, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 2776-2778. (Pubitemid 27157209)
2. E. Zwick, J. Bange, A. Ullrich, Receptor tyrosine kinase signalling as a target for cancer intervention strategies, Endocr. Relat. Cancer 8 (2001) 161-173. (Pubitemid 32947638)
3. A.C. Porter, R.R. Vaillancourt, Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis, Oncogene 17 (1998) 1343-1352. (Pubitemid 28458404)
4. D.R. Robinson, Y.M. Wu, S.F. Lin, The protein tyrosine kinase family of the human genome, Oncogene 19 (2000) 5548-5557.
5. J. Schlessinger, Cell signaling by receptor tyrosine kinases, Cell 103 (2000) 211-225.
6. J. Baselga, J. Arribas, Treating cancer's kinase 'addiction ', Nat. Med. 10 (2004) 786-787.
7. A. Levitzki, A. Gazit, Tyrosine kinase inhibition: an approach to drug development, Science 267 (1995) 1782-1788.
8. A. Petrelli, S. Giordano, From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage, Curr. Med. Chem. 15 (2008) 422-432. (Pubitemid 351472408)
9. J. Dowell, J.D. Minna, P. Kirkpatrick, Erlotinib hydrochloride, Nat. Rev. Drug Discov. 4 (2005) 13-14. (Pubitemid 40109581)
10. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, R. Pazdur, FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets, Oncologist 8 (2003) 303-306. (Pubitemid 36929716)
11. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, S.H. Dickerson, B. Ellis, C. Pennisi, E. Horne, K. Lackey, K.J. Alligood, D.W. Rusnak, T.M. Gilmer, L. Shewchuk, A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells, Cancer Res. 64 (2004) 6652-6659. (Pubitemid 39297926)
12. A. Morabito, M.C. Piccirillo, F. Falasconi, G. De Feo, A. Del Giudice, J. Bryce, M. Di Maio, E. De Maio, N. Normanno, F. Perrone, Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions, Oncologist 14 (2009) 378-390.
13. D. Li, L. Ambrogio, T. Shimamura, S. Kubo, M. Takahashi, L.R. Chirieac, R.F. Padera, G.I. Shapiro, A. Baum, F. Himmelsbach, W.J. Rettig, M. Meyerson, F. Solca, H. Greulich, K.K. Wong, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models, Oncogene 27 (2008) 4702-4711.
14. C.M. Galmarini, Canertinib pfizer, IDrugs 7 (2004) 58-63. (Pubitemid 44313529)
15. G. Marzaro, A. Guiotto, A. Chilin, Quinazoline derivatives as potential anticancer agents: a patent review (2007-2010), Expert Opin. Ther. Pat. 22 (2012) 223-252.
16. A. Chilin, M.T. Conconi, G. Marzaro, A. Guiotto, L. Urbani, F. Tonus, P. Parnigotto, Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold, J. Med. Chem. 53 (2010) 1862-1866.
17. M.T. Conconi, G. Marzaro, A. Guiotto, L. Urbani, I. Zanusso, F. Tonus, M. Tommasini, P.P. Parnigotto, A. Chilin, New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential, Invest. New Drugs 30 (2012) 594-603.
18. G. Shen, Y. Hu, J. Wu, K. Jin, D. Zhu, Y. Zhang, Y. Yu, Y. Lou, A 2,6-disubstituted 4-anilinoquinazoline derivative facilitates cardiomyogenesis of embryonic stem cells, ChemMedChem 7 (2012) 733-740.
19. H. Assefa, S. Kamath, J.K. Buolamwini, 3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, J. Comput. Aided Mol. Des. 17 (2003) 475-493. (Pubitemid 38008961)
20. J.J. Liao, Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors, J. Med. Chem. 50 (2007) 409-424. (Pubitemid 46239775)
21. A. Chilin, G. Marzaro, S. Zanatta, A. Guiotto, A microwave improvement in the synthesis of the quinazoline scaffold, Tetrahedron Lett. 48 (2007) 3229-3231. (Pubitemid 46527753)
22. G. Marzaro, A. Guiotto, G. Pastorini, A. Chilin, A novel approach to quinazolin-4(3H)-one via quinazoline oxidation: an improved synthesis of 4-anilinoquinazolines, Tetrahedron 66 (2010) 962-968.
23. G. Marzaro, A. Chilin, G. Pastorini, A. Guiotto, A novel convenient synthesis of benzoquinazolines, Org. Lett. 8 (2006) 255-256. (Pubitemid 43163976)
24. A.J. Bridges, H. Zhou, D.R. Cody, G.W. Rewcastle, A. McMichael, H.D. Showalter, D.W. Fry, A.J. Kraker, W.A. Denny, Tyrosine kinase inhibitors. 8. An unusually steep structureeactivity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor, J. Med. Chem. 39 (1996) 267-276.
25. J. Folkman, P. Cole, S. Zimmerman, Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment, Ann. Surg. 164 (1966) 491-502.
26. N. Ferrara, R.S. Kerbel, Angiogenesis as a therapeutic target, Nature 438 (2005) 967-974. (Pubitemid 43093963)
27. C. Michiels, T. Arnould, J. Remacle, Endothelial cell responses to hypoxia: initiation of a cascade of cellular interactions, Biochim. Biophys. Acta 1497 (2000) 1-10. (Pubitemid 30330885)
28. B. Hobson, J. Denekamp, Endothelial proliferation in tumours and normal tissues: continuous labelling studies, Br. J. Cancer 49 (1984) 405-413. (Pubitemid 14125248)
29. P. Carmeliet, R.K. Jain, Angiogenesis in cancer and other diseases, Nature 407 (2000) 249-257.
30. V. Levina, Y. Su, B. Nolen, X. Liu, Y. Gordin, M. Lee, A. Lokshin, E. Gorelik, Chemotherapeutic drugs and human tumor cells cytokine network, Int. J. Cancer 123 (2008) 2031-2040.
31. C.H. Heldin, B. Westermark, Mechanism of action and in vivo role of plateletderived growth factor, Physiol. Rev. 79 (1999) 1283-1316. (Pubitemid 29473317)
32. F. Anselmi, M. Orlandini, M. Rocchigiani, C. De Clemente, A. Salameh, C. Lentucci, S. Oliviero, F. Galvagni, c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1, Angiogenesis 15 (2012) 187-197.
33. G. Hu, A.T. Place, R.D. Minshall, Regulation of endothelial permeability by Src kinase signaling: vascular leakage versus transcellular transport of drugs and macromolecules, Chem. Biol. Interact. 171 (2008) 177-189.
34. J.T. Parsons, S.J. Parsons, Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways, Curr. Opin. Cell Biol. 9 (1997) 187-192. (Pubitemid 27135986)
35. D. Srinivasan, R. Plattner, Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells, Cancer Res. 66 (2006) 5648-5655. (Pubitemid 43927117)
36. M. Al-Otaiby, E. Tassi, M.O. Schmidt, C.D. Chien, T. Baker, A.G. Salas, J. Xu, M. Furlong, R. Schlegel, A.T. Riegel, A. Wellstein, Role of the nuclear receptor coactivator AIB1/SRC-3 in angiogenesis and wound healing, Am. J. Pathol. 180 (2012) 1474-1484.
37. R. Gupta, M.L. Maitland, Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity, Curr. Hypertens. Rep. 13 (2011) 430-435.
38. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimeraea visualization system for exploratory research and analysis, J. Comput. Chem. 25 (2004) 1605-1612.
39. Marvin, Version 5.5.0.1, Program B; ChemAxon: Budapest, Hungary; www.chemaxon.com/products.
40. N.M. O'Boyle,M. Banck, C.A. James, C.Morley, T. Vandermeersch, G.R. Hutchison, Open Babel: an open chemical toolbox, J. Cheminf. 3 (2011) 33.
41. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009) 2785-2791.
42. Y. Koyama, T. Barrett, Y. Hama, G. Ravizzini, P.L. Choyke, H. Kobayashi, In vivo molecular imaging to diagnose and subtype tumors through receptortargeted optically labeled monoclonal antibodies, Neoplasia 9 (2007) 1021-1029. (Pubitemid 350255349)
43. V. Gasparotto, I. Castagliuolo, G. Chiarelotto, V. Pezzi, D. Montanaro, P. Brun, G. Palu, G. Viola, M.G. Ferlin, Synthesis and biological activity of 7-phenyl-6,9-dihydro-3H-pyrrolo[3,2-f]quinolin-9-ones: a new class of antimitotic agents devoid of aromatase activity, J. Med. Chem. 49 (2006) 1910-1915.